ICAM-2 Antibody (miC2-4): sc-19682

ICAM-2 Antibody (miC2-4) is a rat monoclonal IgG2a antibody that detects ICAM-2 in mouse samples through immunofluorescence (IF) and flow cytometry (FCM) applications. ICAM-2, also known as CD102, is a crucial member of the intercellular adhesion molecule family, primarily expressed on endothelial cells and leukocytes, where ICAM-2 plays a significant role in mediating leukocyte adhesion and migration during immune responses. ICAM-2′s ability to interact with lymphocyte function-associated antigen-1 (LFA-1) is particularly important, as ICAM-2 facilitates the adhesion of lymphocytes to endothelial cells, thereby promoting their extravasation into tissues during inflammation. Proper functioning of ICAM-2 is vital for maintaining immune homeostasis and responding effectively to pathogens, making ICAM-2 a key player in both innate and adaptive immunity. Dysregulation of ICAM-2 expression has been implicated in various inflammatory diseases, highlighting ICAM-2′s potential as a therapeutic target. Anti-ICAM-2 antibody (miC2-4) is an essential tool for researchers studying immune cell interactions and the underlying mechanisms of immune responses in mouse models.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

ICAM-2 Antibody (miC2-4) References:

1. ICAM-2 expression mediates a membrane-actin link, confers a nonmetastatic phenotype and reflects favorable tumor stage or histology in neuroblastoma.  |  Yoon, KJ., et al. 2008. PLoS One. 3: e3629. PMID: 18978946
2. N-glycosylation of ICAM-2 is required for ICAM-2-mediated complete suppression of metastatic potential of SK-N-AS neuroblastoma cells.  |  Feduska, JM., et al. 2013. BMC Cancer. 13: 261. PMID: 23714211
3. ICAM-2 facilitates luminal interactions between neutrophils and endothelial cells in vivo.  |  Halai, K., et al. 2014. J Cell Sci. 127: 620-9. PMID: 24317296
4. ICAM-2 confers a non-metastatic phenotype in neuroblastoma cells by interaction with α-actinin.  |  Feduska, JM., et al. 2015. Oncogene. 34: 1553-62. PMID: 24704826
5. The physiological roles of ICAM-1 and ICAM-2 in neutrophil migration into tissues.  |  Lyck, R. and Enzmann, G. 2015. Curr Opin Hematol. 22: 53-9. PMID: 25427141
6. Lung ICAM-1 and ICAM-2 support spontaneous intravascular effector lymphocyte entrapment but are not required for neutrophil entrapment or emigration inside endotoxin-inflamed lungs.  |  Petrovich, E., et al. 2016. FASEB J. 30: 1767-78. PMID: 26823454
7. ICAM-1 and ICAM-2 Are Differentially Expressed and Up-Regulated on Inflamed Pulmonary Epithelium, but Neither ICAM-2 nor LFA-1: ICAM-1 Are Required for Neutrophil Migration Into the Airways In Vivo.  |  Chong, DLW., et al. 2021. Front Immunol. 12: 691957. PMID: 34484188
8. Artemisitene suppresses rheumatoid arthritis progression via modulating METTL3-mediated N6-methyladenosine modification of ICAM2 mRNA in fibroblast-like synoviocytes.  |  Chen, J., et al. 2022. Clin Transl Med. 12: e1148. PMID: 36536495
9. ICAM2 is related to good prognosis in dendritic cell immunotherapy for cancer.  |  da Silva, SF., et al. 2024. Immunotherapy. 16: 173-185. PMID: 38126167
10. LFA-1 interaction with ICAM-1 and ICAM-2 regulates Th2 cytokine production.  |  Salomon, B. and Bluestone, JA. 1998. J Immunol. 161: 5138-42. PMID: 9820482

The preferred ICAM-2 antibody is ICAM-2 Antibody (F-5): sc-9987.